219 related articles for article (PubMed ID: 23860529)
21. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
[TBL] [Abstract][Full Text] [Related]
22. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
[TBL] [Abstract][Full Text] [Related]
23. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
[TBL] [Abstract][Full Text] [Related]
24. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
[TBL] [Abstract][Full Text] [Related]
25. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
26. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
27. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
28. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
[TBL] [Abstract][Full Text] [Related]
29. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
30. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
[TBL] [Abstract][Full Text] [Related]
31. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide.
Frampas E; Maurel C; Remaud-Le Saëc P; Mauxion T; Faivre-Chauvet A; Davodeau F; Goldenberg DM; Bardiès M; Barbet J
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2153-64. PubMed ID: 21858527
[TBL] [Abstract][Full Text] [Related]
32. A divalent hapten-peptide induces apoptosis in human non hodgkin lymphoma cell lines targeted by anti-CD20xanti-hapten bispecific antibodies.
Brard PY; Karacay H; Stein R; Sharkey RM; Mattes MJ; Chang CH; Rossi EA; McBride WJ; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5564s-5571s. PubMed ID: 17875790
[TBL] [Abstract][Full Text] [Related]
33. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.
Mirallié E; Saï-Maurel C; Faivre-Chauvet A; Regenet N; Chang CH; Goldenberg DM; Chatal JF; Barbet J; Thedrez P
Eur J Nucl Med Mol Imaging; 2005 Aug; 32(8):901-9. PubMed ID: 15864584
[TBL] [Abstract][Full Text] [Related]
34. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
35. Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
Kraeber-Bodéré F; Salaun PY; Ansquer C; Drui D; Mirallié E; Faivre-Chauvet A; Barbet J; Goldenberg DM; Chatal JF
Tumour Biol; 2012 Jun; 33(3):601-6. PubMed ID: 22396039
[TBL] [Abstract][Full Text] [Related]
36. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
[TBL] [Abstract][Full Text] [Related]
37. A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer.
Elekonawo FMK; Lütje S; Franssen GM; Bos DL; Goldenberg DM; Boerman OC; Rijpkema M
EJNMMI Res; 2019 Sep; 9(1):86. PubMed ID: 31485790
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
[TBL] [Abstract][Full Text] [Related]
39. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
40. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]